Exhibit 99.1

LOGO

 

NEWS RELEASE - for immediate release

Alexza Reports 2015 Second Quarter Financial Results

Management to Review Results and Provide Business Update

in Conference Call Scheduled Today at 5:00 p.m. Eastern Time

Mountain View, California, August 6, 2015

- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended June 30, 2015. The net loss for the second quarter was $12.5 million compared to $6.0 million during the same quarter in 2014. The net loss for the six months ended June 30, 2015 and 2014 was $12.9 million and $16.7 million, respectively. At June 30, 2015, Alexza had consolidated cash, cash equivalents, and marketable securities of $15.7 million.

“We continue to see the incremental growth in the ADASUVE global launch. ADASUVE is now available in 18 countries and we see continued increases in the number of hospitals stocking and using the product,” said Thomas B. King, President and CEO of Alexza Pharmaceuticals. “Importantly, we believe the sales during the ADASUVE launch do not reflect the clinical benefits ADASUVE can convey to patients, and we remain confident in ADASUVE’s long-term commercial prospects. Feedback from physicians and patients corroborate the positive clinical profile we observed with ADASUVE during its clinical development.”

King continued, “Earlier this year we embarked on a plan to change our commercial production strategy to reduce our cash burn rate. We are pleased to have made substantial progress on this plan, including the recent amendments to our Teva and Ferrer agreements. These changes will allow us to reduce the near term spending on ADASUVE production and eliminate the costs associated with some of the EU post-approval commitments, helping us progress on our goal of substantially reducing our cash use.”

King concluded, “Importantly, we remain focused on driving value in Alexza, including seeking additional collaborations for ADASUVE in available markets and working diligently on partnering our validated Staccato platform technology for new product opportunities.”

Alexza Business Updates

 

    In April, Alexza announced the promotions of Dr. Edwin S. Kamemoto to the newly created position of Executive Vice President, R&D and Quality, and Dr. Lori H. Takahashi to the newly created position of Vice President, Pharmaceutical R&D and Quality.

 

    In May 2015, Alexza identified initiatives to reduce Alexza’s underutilized commercial production capacity, while fulfilling the supply requirements of its commercial partners. Teva and Ferrer provided longer-term ADASUVE orders, allowing Alexza to manufacture ADASUVE in a consistent manner to take advantage of the efficiencies of continued batch production. Alexza plans to produce ADASUVE until August 2015. Once orders are filled and shipped, it is Alexza’s intention to suspend ADASUVE commercial production operations. Alexza anticipates that total ADASUVE production for 2015 will be approximately 110,000 units.


The following information was filed by Alexza Pharmaceuticals Inc. (ALXA) on Thursday, August 6, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Alexza Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexza Pharmaceuticals Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account